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Health services researchIntroduction: This study aimed to evaluate the early population impact of Ontario’s school-based human
papillomavirus (HPV) vaccination program, implemented in September 2007 for grade 8 females, by com-
paring anogenital wart (AGW) health care utilization before and after vaccine program implementation,
in program-eligible and program-ineligible cohorts, focusing on 15–26 year olds.
Methods: Using a retrospective longitudinal population-based study design, health administrative data
were used to identify incident AGWs and total health service utilization (HSU) for AGWs for Ontario res-
idents 15 years and older between April 1 2004 and March 31 2014. The study period was divided into
two eras: the pre-vaccine program era and the vaccine program era. Negative binomial models were gen-
erated to analyze trends across time by age group and sex. We adjusted female rates for routine
Papanicolaou (Pap) testing to address spillover effects of Pap smear policy changes on AGW diagnosis.
Results: Between fiscal years 2004 and 2013, AGW incidence decreased 2.6% on average per year in
15–17 year old females, and total HSU for AGWs decreased an average of 4.8% and 2.2% per year in
15–17 and 18–20 year old females. Comparing the vaccine era to the pre-vaccine era, AGW incidence
decreased 6.5% in 18–20 year old females, and AGW HSU decreased 13.8%, 11.1%, and 10.0% in 15–17,
18–20, and 21–23 year old females respectively. In contrast, male AGW incidence rates increased an
average of 4.1%, 2.8%, and 0.9% per year in 15–17, 21–23, and 24–26 year old males respectively. AGW
incidence rates increased 12.2% in 15–17 year old males from the pre-vaccine to vaccine era.
Conclusion: The decline in AGW incidence and HSU in program-eligible females suggests the
school-based HPV vaccination program has had an early population impact in Ontario. The increasing
AGW incidence in males suggests no early evidence of herd effects in males.
Crown Copyright  2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In September 2007, Ontario, Canada’s most populated province
with approximately 13.3 million residents in 2011 [1], imple-
mented a voluntary, publicly-funded school-based human papillo-
mavirus (HPV) vaccination program for grade 8 girls, using the
HPV4 vaccine, Gardasil [2]. Initially a three-dose schedule was
used, but this was modified in the 2015/16 school year to a two-
dose schedule. Evaluating the impact of the program on
population-level cervical cancer incidence in Ontario will require
the passage of substantial time due to the latency period from
HPV infection to cervical cancer; however, health care utilization
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program’s impact in preventing HPV-induced lesions, while also
providing valuable information on the change in the AGW burden.
Researchers from other countries with HPV vaccination programs,
including Australia, the United States (US), Sweden, and Denmark,
have begun reporting significant decreases in the incidence of
AGWs among females, with the greatest reductions in settings
with high vaccine uptake; however, the indirect impact on males
has varied ([3–9], and reviewed by [10–13]).
Our objective was to evaluate the early population impact of
Ontario’s HPV school-based vaccination program on AGWs by
comparing health care utilization for AGWs before and after pro-
gram introduction using health administrative data. We aimed to
estimate the benefits of the program at the population level by
age group and sex.2. Methods
2.1. Population and study period
The population included all Ontario residents 15 years and
older with a valid health card number in Ontario’s health care sys-
tem (described below). Average annual incidence was reported for
individuals 15 years and older, but our analysis of pre-vaccine and
vaccine eras focused on 15–26 year olds as this is the age group
where we would likely see the earliest and greatest population
impact on AGWs given the age eligibility of the vaccine program.
In our analysis, the year started on April 1 and ended March 31
in keeping with the fiscal calendar, and the study period was April
1 2003 to March 31 2014 (years 2003–2013). The first year of the
study period was used as a wash-out year to exclude prevalent
cases (see Outcome Definition). The study period was divided into
two eras: the pre-vaccine program era (2004–2007), and the vac-
cine program era (2008–2013). Although Ontario’s program was
implemented in September 2007, the full first series of HPV4 vac-
cination would have been completed between March and May
2008, hence April 1 2008 was designated as the start of the vaccine
program era. Grade 8 girls are eligible for the program, most of
whom are 13 years of age by December 31 of the calendar year
in which they are in grade 8. For the purposes of this study we
defined the program eligible cohort during the vaccine program
era as females born between January 1 1994 and December 31
2000 (aged 14–20 years in 2013). We did not have individual-
level data on HPV4 vaccination status.2.2. Data sources
Health administrative data has been used to estimate AGW bur-
den in other studies [6,7,14–18]. Health care encounters captured
by the provincial insurance plan data were used to measure
AGW-related health care utilization. Ontario provides health care
coverage to all residents through the Ontario Health Insurance Pro-
gram (OHIP). Eligibility requires that an individual be a Canadian
citizen, landed immigrant, or refugee, has Ontario as their primary
or permanent home, and resides in Ontario for at least 153 days
over a 12-month period. There is no parallel system of private ser-
vices for routine medical care and hospitalizations. Individual-level
outpatient physician visits for AGWs were captured within the
OHIP database, which represents approximately 90% of AGW
health service visits captured by the provincial health insurance
administrative databases [16]. The Registered Persons Database
(RPDB) contains information on all Ontario residents who are eligi-
ble for health care coverage and was used to determine population
size, sex, and date of birth. These datasets were linked usingunique encoded identifiers and analyzed at the Institute for Clinical
Evaluative Sciences (ICES).
2.3. Outcome definitions
Consistent with previous health services studies on AGWs, an
episode of AGWs was deemed incident if it was preceded by a
12-month window without any AGW-related care utilization
[9,15–18]. In addition to AGW incidence, we report total AGW
HSU rates, which counted every health care encounter that fulfilled
the AGW outcome definition in the numerator. As described fur-
ther elsewhere, the OHIP database provides diagnostic and proce-
dural codes from physician office visits that can be combined into
algorithms to generate a probable outcome definition for AGWs
[16,19]. A physician office visit was counted as an AGW visit if
any of the following ten code combinations were billed: 099 only
if billed with Z117; or, 079 only if billed with Z117; or, 629 only
if billed with Z117; or, Z549; or, Z758; or, Z733, Z736, or Z769 only
in females; or, Z767 or Z701 only in males [16].
2.4. Statistical analysis
We analyzed annual AGW HSU rates and incidence per 1000
population across the study period stratified by sex and age group
among 15–26 year olds. The crude rates were calculated by divid-
ing the numerator (number of prevalent AGW cases stratified by
fiscal year, gender, and age group) by the denominator (size of
the Ontario population in the same fiscal year, gender and age
group). We then modeled the numerator count as the outcome
and fiscal year as the independent continuous variable in the neg-
ative binomial regression models with the log link function and log
(population) as the offset. Average annual rates are reported by era
and are the average of the annual HSU or incidence rates for each
year in a given era. A negative binomial regression model was also
used to model incidence or HSU rates by year. Considering that
some AGWs diagnosed at the time of routine Papanicolaou (Pap)
testing might not otherwise be diagnosed, we adjusted for the
impact of changes in Pap testing rates resulting from revisions to
Ontario’s cervical screening guidelines in 2011 and associated
changes to OHIP Pap testing reimbursement for physicians in
2012. As we are examining changes over time, we wanted to
ensure this potential change in outcome identification was
adjusted for. We used established billing codes to identify Pap tests
(Supplemental Table S1) [19,20]. Visits meeting the Pap test out-
come definition occurring 12 months or more apart were consid-
ered as routine screening visits. After we calculated the Pap
testing rates, they were adjusted in the negative binomial model
as a continuous variable for females, with unadjusted rates
explored in a sensitivity analysis. Reported percent changes were
the average annual change between 2004 and 2013, relative to
2004, or between the pre-vaccine and vaccine eras (Supplemental
Table S2). The threshold for statistical significance was set at
p < 0.05. Analyses were performed using SAS, 9.3 (The SAS Insti-
tute, Cary, NC) and Microsoft Excel 2010.
This study was approved by the Research Ethics Board at Sun-
nybrook Health Sciences Centre and the Ethics Review Board at
Public Health Ontario.3. Results
3.1. AGW counts, AGW sex and age distribution
Between April 1 2004 and March 31 2014, 113029 individuals
15 years and older made 286609 health care visits for AGWs
through physician offices. In the pre-vaccine and vaccine eras the
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individuals 15 years and older was 2.74 and 2.61 per 1000 popula-
tion, respectively. The average annual incidence of AGWs based on
physician office visits among individuals 15 years and older was
1.17 and 1.15 per 1000 population in the pre-vaccine and vaccine
eras, respectively. The average annual AGW incidence varied by
age group and sex (Fig. 1), similar to our previous report [16].
AGW incidence peaked in 21–23 year old females and males. Aver-
age annual incidence was higher in females than males who were
15–23 years old, but males had a higher average annual incidence
from 27 to 41 years of age, while the rate was similar between both
sexes in individuals 24–26 years and 42 years and older.3.2. AGW incidence
Between 2004 and 2013, Pap test rate-adjusted AGW incidence
decreased significantly by an average of 2.6% per year in
15–17 year old females (p = 0.04), but decreased non-significantly
in 18–20 and 21–23 year old females and increased non-
significantly in 24–26 year old females. In contrast, between
2004 and 2013 male AGW incidence increased significantly by an
average of 4.1%, 2.8%, and 0.9% per year in 15–17, 21–23, and
24–26 year old males respectively (p = 0.01, p < 0.0001, p = 0.05).
Among 18–20 year old males there was a non-significant increase
in AGW incidence from 2004 to 2013, however we did observe a
sharp decrease from 2010 to 2013 in this age group (Fig. 2).
AGW incidence between the pre-vaccine and vaccine eras differed
significantly for certain age groups. Pap test rate-adjusted AGW
incidence decreased significantly between the pre-vaccine and
vaccine eras by 6.5% in 18–20 year old females (p = 0.03), and
decreased non-significantly in 15–17 and 21–23 year old females,
and increased non-significantly among 24–26 year old females.
For males, AGW incidence increased significantly between the
pre-vaccine and vaccine eras by 12% in 15–17 year olds (p = 0.04)
and increased non-significantly among males 18 to 26 years of age.3.3. AGW total HSU
Between 2004 and 2013, Pap rate-adjusted AGW HSU rates
decreased significantly by an average of 4.8% and 2.2% per year
in 15–17 and 18–20 year old females respectively (p = 0.0003,
p = 0.01), and decreased non-significantly among 21–23 year old
females and increased non-significantly in 24–26 year old females4
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Fig. 1. Average annual incidence of AGWs captured by physician office visits 2004–
2013, by sex and age group, for females (adjusted for Pap testing rate) and males
(crude).(Fig. 3). Among males there were no significant changes, however,
AGW HSU rates decreased non-significantly in 15–17, 21–23, and
24–26 year olds, and increased in 18–20 year olds. Comparing
the pre-vaccine and vaccine eras, AGW HSU rates differed signifi-
cantly for certain age groups. Age specific analysis revealed Pap
test rate-adjusted AGW HSU rates decreased significantly between
the pre-vaccine and vaccine eras by 13.8%, 11.1%, and 10.0% in
15–17, 18–20, and 21–23 year old females respectively (p = 0.01,
p < 0.0001, p = 0.004), and decreased non-significantly in
24–26 year old females. Among males there were no significant
changes, however, AGW HSU rates decreased non-significantly
between the pre-vaccine and vaccine eras in 15–17 and 21–23 year
olds, and increased in 18–20 and 24–26 year olds.3.4. Sensitivity analysis
Without adjusting for Pap test rates there were additional sig-
nificant findings. AGW incidence decreased significantly by an
average of 5.8%, 4.8%, 3.0%, and 2.0% per year in 15–17, 18–20,
21–23, and 24–26 year old females respectively (p < 0.0001,
p < 0.0001, p < 0.0001, p = 0.008), and between the pre-vaccine
and vaccine eras AGW incidence decreased significantly by 21.2%,
18.6%, and 12.3% in 15–17, 18–20, and 21–23 year old females
(p = 0.01, p = 0.02, p = 0.01), but decreased non-significantly in
24–26 year olds. Without adjusting for Pap test rates, AGW HSU
rates decreased significantly by an average of 4.8%, 5.2%, 4.7%,
and 2.4% per year in 15–17, 18–20, 21–23, and 24–26 year old
females respectively (p < 0.0001, p < 0.0001, p < 0.0001,
p = 0.0006), and between the pre-vaccine and vaccine eras, AGW
HSU rates decreased significantly by 20.8%, 21.8%, and 20.5% in
15–17, 18–20, and 21–23 year old females respectively
(p = 0.0004, p = 0.001, p = 0.001), but decreased non-significantly
in 24–26 year old females.4. Discussion
This study provides evidence of the early population-level
impact of a school-based HPV vaccination program on AGWs in
Canada’s most populated province, Ontario. Our findings that
AGW incidence and HSU rates have significantly decreased in some
female age groups since the introduction of the HPV vaccination
programs are consistent with results of similar studies and several
reviews [5,9–13,21]. In contrast, incidence rates have significantly
increased among similar male age groups over the same study
period while no significant changes were seen in male AGW HSU.
Modeling and ecological studies have reported variable levels of
impact on HPV infection in males through herd effects after imple-
mentation of female-targeted HPV vaccination programs. Estimates
of HPV vaccine coverage among the target grade 8 female cohort eli-
gible for the publicly-funded program increased from 51% in 2007/8
to 58% in 2008/9, and then remained steady at 59% and 58% for
2009/10 and 2010/11, respectively, before increasing to 70% in
2011/12 and then 80% in 2012/13 [22]. Although coverage has
increased since the introduction of the program, up to the
2012/2013 school year, the program has not met its target of 90%
set by the Canadian Immunization Committee [23]. Suboptimal cov-
erage in the first several years of the program may explain why we
did not observe evidence of herd effects in adolescent males in the
early years of the vaccine era. In fact, AGW incidence rates increased
significantly in certain male age groups in Ontario from the pre-
vaccine to vaccine era, and across the study period by year. As the
cohorts of vaccine eligible females get older and approach the peak
age of AGW incidence and as HPV vaccine coverage increases, we
may see evidence of indirect vaccine impact in Ontario males. The
decreasing incidence among 18–20 year old males in the most
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Fig. 2. Annual incident AGWs captured by physician office visits in 15–26 year olds, 2004–2013, for females (adjusted for Pap testing rate) and males (crude). Statistical
significance reflects average annual changes in incidence relative to 2004.
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tained effect. One explanation is that this decrease is an early reflec-
tion of herd effects as female and male sexual partnering tends to
involve partnering between younger females and slightly older
males [24–26]. It is interesting to note thatwedidnot observe a sim-
ilar decrease in 15–17 year old males in recent years.
The HPV vaccine was recommended by Canada’s National Advi-
sory Committee on Immunization (NACI) for females 9–26 years of
age in the early years of licensure, which extends beyond the age
group targeted in the publicly funded program [27]. The significant
decrease in AGW HSU rate in 21–23 year old females, who would
not have been eligible for the publicly-funded program, may reflect
private HPV vaccine purchase. From the launch of Gardasil in
August 2006 to December 2013, it is estimated that 523160 doses
were privately purchased (personal communication with Merck
Canada).
Smith et al. recently reported early benefits of the Ontario HPV
vaccination program on cervical dysplasia and also explored AGWs[28]. In contrast to our study, that study reported impact based on
program eligibility and individual-level vaccination status, and
observed statistically significant protective effects of program eli-
gibility and vaccination on cervical dysplasia, but no statistically
significant impact on AGWs. Our study differs by providing a
population-level assessment with age bands corresponding to the
program eligible cohort without considering individual level vacci-
nation data in order to reflect population impact. In Ontario, AGW
incidence peaks among 21–23 year olds, and this could explain the
non-significant effect on AGWs reported by Smith and colleagues,
who studied a younger population with lower AGW incidence.
The finding that adjustment by Pap test rate changed the size
and statistical significance of AGW trends suggests that AGWs
may be diagnosed incidentally through a pelvic exam conducted
during a Pap test visit. The sensitivity analysis suggests that anal-
yses unadjusted for Pap test rates may overestimate the change in
AGW burden and that adjusted rates may underestimate the
changes. As Pap testing is part of the clinical care pathway that
4682 F.M. Guerra et al. / Vaccine 34 (2016) 4678–4683results in a diagnosis, analyses evaluating the HPV program need to
consider the role, if any, that changes in Pap testing could have on
their findings.
There are several limitations to consider when interpreting the
results of this study, including those described previously [16]. As a
population-based assessment, there are a number of factors that
could have influenced the observed trends aside from the HPV vac-
cine program. For example, the increasing use of urine screening
for chlamydia as opposed to gynecological exam with swabs may
have reduced the number of AGW cases diagnosed incidentally.
Secondly, our reliance on cryotherapy and chemical therapy codes
for the AGW case definition underestimated the true burden of
AGWs because topical, patient-applied treatments are not cap-
tured in the health administrative data. If treatment practices
changed during the study period to incorporate more topical,
patient-applied treatments, then this would contribute to a reduc-
tion in AGW cases and HSU, because individuals with AGW who
self-treat would not be captured through cryotherapy and chemi-
cal codes. Decreasing sexual activity with concomitant lower risk
of sexually-transmitted infection among our target age groups
could explain some of our results. Data from nationally representa-
tive surveys of adolescent sexual behavior demonstrated that the
percentage of 15–19 year old Canadians reporting at least one act
of sexual intercourse declined from 47% in 1996/1997 to 43% in
2005 entirely due to behavior of the female population [29]. We
do not know if this trend continued through our study period,
although this would unlikely account for the magnitude of the
changes we have observed in AGWs, and the discordant sex-
specific changes. It is important to note that the HPV vaccine itself,
however, has not been identified as a potential driver of changes to
sexual practices [19,30,31]. Reporting AGW incidence and HSU
rates based on records in the OHIP database is an underestimate
of total AGW rates in Ontario, where individuals can be diagnosed
and treated at emergency departments (ED), hospitals, same day
surgery (SDS) clinics, sexual health clinics, community health cen-
tres, and public health clinics, none of which are captured in the
database used in our study. We did look at AGW HSU at ED, hospi-
tals, and SDS clinics, but these comprised only an additional 9% of
visits. As this limitation applies to the whole study period, it should
not affect inferences regarding trends across the study period as
there is no known reason for a shift in an individual’s choice in type
of health services sought for AGWs during this period. However, if
people attending these alternate clinics have a different probability
of either being vaccinated or having AGWs, we could have over- or
under-estimated that population effect. Finally, we did not have
access to individual level HPV vaccination data, so we were not
able to assess if any of the individuals with AGWs were vaccinated.5. Conclusions
By comparing AGW incidence and HSU rates by age group and
sex over time, this study estimates the impact of the HPV vaccina-
tion program in Ontario at the population level and provides pre-
liminary insight into the benefits of the current program and
potential indirect effects among males. Our analysis suggests a sig-
nificant impact of the Ontario HPV vaccination program on AGW
rates in young adult females, but no evidence of herd effects on
males. Continued assessment is needed to provide further evidence
of program impact, especially as boys will be eligible to receive the
HPV vaccine through the school-based program beginning in the
2016/17 school year.Competing interests
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